Sleep for Health & Longevity - Quick Reference Sheet

Sleep for Health & Longevity

Created on 09/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

The link between how people sleep and how long they live is large and repeatedly found, but almost none of it has been tested by assigning people to sleep more. Firmest evidence: alertness, clear thinking, mood, and treating broken sleep. For someone already doing the rest well, the target is the same hours at the same time every night. (Full Review)

Protocol

Fixed wake time first
Constant rise time, 7 days a week
Weekends included. The single lever that stabilises circadian timing and drives the regularity metric.
Morning outdoor light
10–30 min within an hour of waking
Longer on overcast days. Retinal input resets the body clock.
Sleep opportunity window
~30 min above measured average sleep time
For most adults 7–8.5 hours. Extending further reduces efficiency without adding sleep.
Time to effect
Alertness and mood
3–7 nights
Of consistently adequate sleep.
Behavioural insomnia treatment
Weeks 3–4
Typical point at which benefit shows.
Metabolic and cardiovascular markers
Months
Where they move at all.

Benefits

Contraindications
  • Populations who should avoid Sleep: None identified
  • Populations who should not attempt unsupervised sleep restriction or self-directed sleep protocols:
  • Bipolar disorder or a history of mania
  • Epilepsy or a seizure history
  • Untreated obstructive sleep apnea (STOP-Bang 3 or higher, or a witnessed apnea), pending evaluation
  • Commercial drivers, pilots, operators of heavy machinery (during any restriction phase)
  • Pregnancy in the third trimester
  • Narcolepsy or idiopathic hypersomnia
Key Interactions
  • Sedative-hypnotics (zolpidem, zopiclone, temazepam)
  • Over-the-counter antihistamine sleep aids (diphenhydramine, doxylamine)
  • Alcohol
  • Beta-blockers (metoprolol, propranolol)
  • Stimulants and wakefulness agents (methylphenidate, modafinil, high-dose caffeine)
  • Corticosteroids (prednisone, dexamethasone)
  • Melatonin supplements
  • Magnesium and glycine
  • Valerian (Valeriana officinalis) and ashwagandha (Withania somnifera)
  • Antidepressants (SSRIs and venlafaxine)
  • Other interventions (late eating windows, evening training, evening sauna)

Risk & Side Effects

  • High: Daytime sleepiness and impaired vigilance during sleep-restriction therapy; adverse effects of hypnotic medication used to force sleep
  • Medium: Excess mortality and morbidity associated with long sleep (conflicted); circadian phase shifts and next-day sedation from mistimed melatonin
  • Low: Orthosomnia, anxiety driven by sleep tracking; masking of undiagnosed obstructive sleep apnea
  • Speculative: Blunted endogenous melatonin rhythm from long-term nightly supplementation

Monitoring

Marker Target Why
Sleep Regularity Index (SRI) 85 or higher on a 0–100 scale Timing consistency predicts mortality more strongly than duration does
Average nightly sleep duration 7.0–8.5 hours of actual sleep The exposure the entire epidemiology is built on
Sleep efficiency 85–92% Separates short sleep from fragmented sleep, and flags over-extension
Insomnia Severity Index (ISI) 0–7 Validated symptom scale that tracks response to behavioural treatment
Epworth Sleepiness Scale (ESS) 0–8 Detects residual daytime sleepiness that adequate opportunity has not resolved
STOP-Bang score 0–2 Screens for obstructive sleep apnea before any self-directed protocol
Fasting glucose 75–86 mg/dL Sleep restriction lowers insulin sensitivity within days
HbA1c 4.9–5.4% Integrates months of glucose exposure, so it survives single-night noise
hs-CRP Below 1.0 mg/L Tracks the inflammatory signal associated with disturbed sleep
Morning blood pressure Below 120/80 mmHg Short sleep tracks with incident hypertension in cohort data
Overnight heart-rate variability (HRV) No established population target; stability or rise against the individual's own 30-day baseline Early, sensitive signal of alcohol, late meals, overtraining or illness
Morning resting heart rate Within 3 beats per minute of the individual's own baseline Rises with alcohol, late training and illness before subjective symptoms appear
Serum ferritin 50–100 ng/mL in women, 50–150 ng/mL in men Low iron stores drive restless legs, a common and treatable cause of fragmented sleep
Total testosterone (men) 500–800 ng/dL Sleep restriction measurably lowers it, making it a concrete response marker
Serum TSH 0.5–2.0 mIU/L Thyroid dysfunction mimics both insomnia and excessive sleepiness

Cadence: Baseline over at least fourteen nights before any change. Sleep diary and device trends weekly; symptom scales at four and twelve weeks; blood panel and blood pressure at three months, then every six to twelve months.

Qualitative Assessment

  • Time to feeling fully alert after waking, and whether an alarm is needed at all
  • Mid-afternoon energy, and whether a caffeine dose after midday feels necessary
  • Cognitive clarity on demanding work in the first three hours of the day
  • Emotional reactivity and irritability, which shift earlier than any measured biomarker
  • Whether waking during the night is followed by a rapid return to sleep or by rumination
  • Perceived training recovery and willingness to start a planned session